A two-year clinical and economic follow-up of patients on clozapine.
The long-term efficacy of clozapine therapy and its effect on health care costs were examined over a two-year period. Patients on clozapine showed marked clinical improvement as measured by the Brief Psychiatric Rating Scale. They also had significantly lower rates of rehospitalization and hospitalization costs than a comparison group of schizophrenic patients who received standard neuroleptic treatment and who were considerably less psychotic at hospital admission. By the second year of the study, savings on mental health care costs averaged $20,000 for each patient on clozapine therapy. The savings were due largely to the patients' change in residence from costly inpatient facilities to less expensive settings in the community.
Biomedical Operations Department, Sandoz Research Institute, East Hanover, New Jersey.
G
G
Honigfeld
J
J
Patin
D000380:Agranulocytosis / Q000139:chemically induced; D002908:Chronic Disease; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use*; D015331:Cohort Studies; D003363:Cost Control / Q000639:trends; D003984:Dibenzazepines / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006801:Humans; D010359:Patient Readmission / Q000191:economics; D012559:Schizophrenia / Q000188:drug therapy* / Q000191:economics; D012565:Schizophrenic Psychology; D012640:Seizures / Q000139:chemically induced
D003984:Dibenzazepines; D003024:Clozapine